Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Beta Bionics (Nasdaq: BBNX) has successfully completed its upsized initial public offering, raising $234.6 million. The company sold 13,800,000 shares of common stock at $17.00 per share, including the full exercise of the underwriters' option for 1,800,000 additional shares. The IPO generated approximately $212.1 million in gross proceeds for Beta Bionics before expenses.
Additionally, the company conducted a concurrent private placement of 1,000,000 shares at the IPO price to an existing investor, bringing total gross proceeds to approximately $229.1 million. Trading began on the Nasdaq Global Market on January 30, 2025, under the ticker symbol 'BBNX'. The offering was led by BofA Securities, Piper Sandler, and Leerink Partners as lead bookrunners, with Stifel as bookrunner and Lake Street Capital Markets as co-manager.
Beta Bionics (Nasdaq: BBNX) ha completato con successo la sua offerta pubblica iniziale aumentata, raccogliendo 234,6 milioni di dollari. L'azienda ha venduto 13.800.000 azioni ordinarie a 17,00 dollari per azione, compresa l'esercitazione completa dell'opzione degli underwriter per 1.800.000 azioni aggiuntive. L'IPO ha generato circa 212,1 milioni di dollari di proventi lordi per Beta Bionics prima delle spese.
Inoltre, l'azienda ha condotto un collocamento privato concomitante di 1.000.000 azioni al prezzo dell'IPO a un investitore esistente, portando il totale dei proventi lordi a circa 229,1 milioni di dollari. Le contrattazioni sono iniziate sul Nasdaq Global Market il 30 gennaio 2025, sotto il simbolo 'BBNX'. L'offerta è stata guidata da BofA Securities, Piper Sandler e Leerink Partners come bookrunner principali, con Stifel come bookrunner e Lake Street Capital Markets come co-manager.
Beta Bionics (Nasdaq: BBNX) ha completado con éxito su oferta pública inicial aumentada, recaudando 234,6 millones de dólares. La empresa vendió 13.800.000 acciones ordinarias a 17,00 dólares por acción, incluyendo el ejercicio completo de la opción de los suscriptores para 1.800.000 acciones adicionales. La OPI generó aproximadamente 212,1 millones de dólares en ingresos brutos para Beta Bionics antes de gastos.
Adicionalmente, la empresa llevó a cabo una colocación privada concurrente de 1.000.000 de acciones al precio de la OPI a un inversionista existente, llevando el total de ingresos brutos a aproximadamente 229,1 millones de dólares. Las operaciones comenzaron en el Nasdaq Global Market el 30 de enero de 2025, bajo el símbolo 'BBNX'. La oferta fue liderada por BofA Securities, Piper Sandler y Leerink Partners como principales bookrunners, con Stifel como bookrunner y Lake Street Capital Markets como co-gestor.
베타 바이오닉스 (Nasdaq: BBNX)는 업사이즈된 신규 상장 공모를 성공적으로 완료하여 2억 3천460만 달러를 조달했습니다. 이 회사는 주당 17.00달러에 13,800,000주를 판매했으며, 1,800,000주의 추가 주식을 위한 인수자의 옵션을 전부 행사했습니다. IPO는 비용 전에 베타 바이오닉스에 약 2억 1천210만 달러의 총 수익을 창출했습니다.
또한, 회사는 기존 투자자에게 IPO 가격으로 1,000,000주를 동시에 사모 배정하여 총 총수익이 약 2억 2천910만 달러로 증가했습니다. 거래는 2025년 1월 30일에 'BBNX'라는 코드명으로 Nasdaq Global Market에서 시작되었습니다. 이 공모는 BofA Securities, Piper Sandler 및 Leerink Partners가 주간사로 이끌었고, Stifel이 주간사로, Lake Street Capital Markets가 공동 관리자로 참여했습니다.
Beta Bionics (Nasdaq: BBNX) a réussi à finaliser son introduction en bourse augmentée, levant 234,6 millions de dollars. L'entreprise a vendu 13 800 000 actions ordinaires à 17,00 dollars par action, y compris l'exercice complet de l'option des souscripteurs pour 1 800 000 actions supplémentaires. L'IPO a généré environ 212,1 millions de dollars de recettes brutes pour Beta Bionics avant déductions.
De plus, l'entreprise a réalisé un placement privé concomitant de 1 000 000 actions au prix de l'IPO pour un investisseur existant, portant le total des recettes brutes à environ 229,1 millions de dollars. Les échanges ont commencé sur le Nasdaq Global Market le 30 janvier 2025, sous le symbole 'BBNX'. L'offre a été dirigée par BofA Securities, Piper Sandler et Leerink Partners en tant que chefs de file, avec Stifel en tant que livreur principal et Lake Street Capital Markets en tant que co-gérant.
Beta Bionics (Nasdaq: BBNX) hat erfolgreich seine aufgestockte Aktienemission abgeschlossen und 234,6 Millionen Dollar eingenommen. Das Unternehmen verkaufte 13.800.000 Stammaktien zu 17,00 Dollar pro Aktie, einschließlich der vollständigen Ausübung der Option der Underwriter für 1.800.000 zusätzliche Aktien. Der Börsengang generierte etwa 212,1 Millionen Dollar Bruttoerlös für Beta Bionics vor Abzügen.
Zusätzlich führte das Unternehmen eine gleichzeitige Privatplatzierung von 1.000.000 Aktien zum IPO-Preis an einen bestehenden Investor durch, wodurch sich die Gesamtbruttoerlöse auf etwa 229,1 Millionen Dollar erhöhen. Der Handel begann am 30. Januar 2025 an der Nasdaq Global Market unter dem Tickersymbol 'BBNX'. Die Emission wurde von BofA Securities, Piper Sandler und Leerink Partners als Hauptbuchführer geleitet, während Stifel als Buchführer und Lake Street Capital Markets als Co-Manager fungierten.
- Successfully raised $234.6 million through IPO and private placement
- Full exercise of underwriters' option indicates strong market demand
- Additional $17 million raised through concurrent private placement from existing investor
- Significant portion of IPO shares (1,325,000) came from selling stockholders, not generating proceeds for the company
Insights
The successful completion of Beta Bionics' IPO represents a significant milestone in the medical device sector, particularly notable for its substantial oversubscription and full exercise of the underwriters' option. The
The participation of heavyweight investment banks as lead bookrunners - BofA Securities, Piper Sandler and Leerink Partners - adds considerable credibility to the offering. These institutions' involvement typically signals strong institutional interest and thorough due diligence of the company's business model and growth prospects.
A particularly noteworthy aspect is the concurrent
The pricing at
- Accelerated R&D investments in diabetes management solutions
- Expansion of commercial infrastructure
- Strategic acquisitions or partnerships
- Working capital for manufacturing scale-up
IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of its upsized initial public offering of 13,800,000 shares of common stock, including the full exercise of the underwriters’ option to purchase 1,800,000 additional shares, consisting of 475,000 additional shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus, at a price to the public of
BofA Securities, Piper Sandler, and Leerink Partners acted as lead bookrunners for the offering. Stifel acted as a bookrunner and Lake Street Capital Markets acted as co-manager for the offering.
Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on January 29, 2025. A copy of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering was made only by means of a prospectus forming part of the registration statements relating to these securities. Copies of the final prospectus relating to the initial public offering may be obtained from: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924, or by email at prospectus@psc.com; or Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com.
In addition, Beta Bionics sold 1,000,000 shares of its common stock in a concurrent private placement to one of its existing investors at the initial public offering price of
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD.
Investor Relations Contact:
Blake Beber, Head of Investor Relations, ir@betabionics.com
Media and Public Relations Contact:
Karen Hynes, Vice President of Marketing, media@betabionics.com
FAQ
How much did Beta Bionics raise in its January 2025 IPO?
What was the IPO price for BBNX shares?
When did BBNX stock begin trading on Nasdaq?
How many shares were sold in Beta Bionics' IPO?
Who were the lead underwriters for the BBNX IPO?
